Literature DB >> 7159071

Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.

R N Jones, R R Packer.   

Abstract

Enterobacteriaceae strains having elevated minimal inhibitory concentrations (greater than or equal to 2.0 to less than or equal to 32 micrograms/ml) of cefoperazone, cefotaxime, ceftazidime, and moxalactam were synergistically inhibited by amikacin combinations (54.1 to 69.6% occurrence). Indifference was rare (8.1% for moxalactam), and true antagonistic interactions were not observed. Strains resistant or susceptible to these new cephalosporins were also synergistically inhibited by the addition of amikacin, reducing resistant cephalosporin minimal inhibitory concentrations to clinically achievable levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159071      PMCID: PMC185706          DOI: 10.1128/AAC.22.6.985

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Interactions between aminoglycoside antibiotics and carbenicillin or ticarillin.

Authors:  H A Holt; J M Broughall; M McCarthy; D S Reeves
Journal:  Infection       Date:  1976       Impact factor: 3.553

2.  Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.

Authors:  K P Fu; H C Neu
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

3.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.

Authors:  R N Jones; A L Barry; P C Fuchs; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

5.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

7.  The comparative synergistic activity of amikacin, gentamicin, netilmicin and azlocillin, mezlocillin, carbenicillin and ticarcillin against Serratia marcescens.

Authors:  K P Fu; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1978-02       Impact factor: 2.649

8.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates.

Authors:  K E Price; M D DeFuria; T A Pursiano
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

View more
  10 in total

1.  In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  M D Lyon; K R Smith; M S Saag; G A Cloud; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

Review 2.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

4.  In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

Authors:  R N Jones; A L Barry; R R Packer; W W Gregory; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

5.  Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

6.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; N P Zissis; G Tagari; J Bouzos
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.

Authors:  P Angehrn
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 9.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 10.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.